{
    "id": 22273,
    "fullName": "BCOR mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "BCOR mutant indicates an unspecified mutation in the BCOR gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 54880,
        "geneSymbol": "BCOR",
        "terms": [
            "BCOR",
            "ANOP2",
            "MAA2",
            "MCOPS2"
        ]
    },
    "variant": "mutant",
    "createDate": "05/09/2016",
    "updateDate": "10/23/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6206,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In multiple clinical analyses, internal tandem duplications of the BCOR gene were consistently found in clear cell sarcoma of the kidney (PMID: 26098867, PMID: 26516930, PMID: 26573325, PMID: 26150234), suggesting that this may serve as a future diagnostic biomarker.",
            "molecularProfile": {
                "id": 22834,
                "profileName": "BCOR mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4880,
                "name": "kidney clear cell sarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5449,
                    "pubMedId": 26098867,
                    "title": "Consistent in-frame internal tandem duplications of BCOR characterize clear cell sarcoma of the kidney.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26098867"
                },
                {
                    "id": 5450,
                    "pubMedId": 26516930,
                    "title": "Whole transcriptome sequencing identifies BCOR internal tandem duplication as a common feature of clear cell sarcoma of the kidney.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26516930"
                },
                {
                    "id": 5451,
                    "pubMedId": 26573325,
                    "title": "Recurrent internal tandem duplications of BCOR in clear cell sarcoma of the kidney.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26573325"
                },
                {
                    "id": 5452,
                    "pubMedId": 26150234,
                    "title": "Kidney cancer: BCOR mutations that might help in diagnosis of CCSK.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26150234"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13675,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "BCOR mutations, including those at codon N1425, are associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).",
            "molecularProfile": {
                "id": 22834,
                "profileName": "BCOR mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 50908,
                "name": "myelodysplastic syndrome",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16478,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, co-occurrence of BCOR and RUNX1 mutations correlated with sensitivity to Xeljanz (tofacitinib) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).",
            "molecularProfile": {
                "id": 31640,
                "profileName": "BCOR mut RUNX1 mut"
            },
            "therapy": {
                "id": 941,
                "therapyName": "Tofacitinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14523,
                    "pubMedId": 30333627,
                    "title": "Functional genomic landscape of acute myeloid leukaemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30333627"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16477,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, co-occurrence of BCOR and RUNX1 mutations correlated with sensitivity to Jakafi (ruxolitinib) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).",
            "molecularProfile": {
                "id": 31640,
                "profileName": "BCOR mut RUNX1 mut"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14523,
                    "pubMedId": 30333627,
                    "title": "Functional genomic landscape of acute myeloid leukaemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30333627"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16479,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, co-occurrence of BCOR and RUNX1 mutations correlated with sensitivity to Pyridone 6 (CMP6) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).",
            "molecularProfile": {
                "id": 31640,
                "profileName": "BCOR mut RUNX1 mut"
            },
            "therapy": {
                "id": 2797,
                "therapyName": "Pyridone 6",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14523,
                    "pubMedId": 30333627,
                    "title": "Functional genomic landscape of acute myeloid leukaemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30333627"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16476,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, co-occurrence of BCOR and RUNX1 mutations correlated with sensitivity to Momelotinib (CYT387) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).",
            "molecularProfile": {
                "id": 31640,
                "profileName": "BCOR mut RUNX1 mut"
            },
            "therapy": {
                "id": 823,
                "therapyName": "Momelotinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14523,
                    "pubMedId": 30333627,
                    "title": "Functional genomic landscape of acute myeloid leukaemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30333627"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 22834,
            "profileName": "BCOR mutant",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31640,
            "profileName": "BCOR mut RUNX1 mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}